{"id":"advair-hfa","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Headache"},{"rate":"2-5%","effect":"Nervousness/anxiety"},{"rate":"1-3%","effect":"Palpitations"},{"rate":"2-5%","effect":"Oral candidiasis"},{"rate":"5-10%","effect":"Throat irritation"}]},"_chembl":null,"_dailymed":{"setId":"dfaca6f9-3277-47b2-319d-1377917cb54c","title":"ADVAIR HFA (FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE) AEROSOL, METERED [GLAXOSMITHKLINE LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained symptom control.","oneSentence":"Advair HFA combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchodilation in asthma and COPD.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:13.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00235053","phase":"PHASE4","title":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","status":"COMPLETED","sponsor":"Allergy & Asthma Medical Group & Research Center","startDate":"2005-08","conditions":"Asthma, Candidiasis, Oral, Voice Disorders","enrollment":13},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT06025214","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-22","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05982990","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT05697003","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-02-17","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT05085587","phase":"PHASE1","title":"Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-10-01","conditions":"Bioequivalence, Asthma","enrollment":18},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT04746040","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-01-18","conditions":"Bioequivalence, Asthma","enrollment":50},{"nctId":"NCT04790838","phase":"","title":"Pooled Analysis FP_SX_250_50","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-06-02","conditions":"Asthma","enrollment":82},{"nctId":"NCT04546256","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-09-01","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT04466176","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-07-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02024204","phase":"NA","title":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-04-09","conditions":"Lung Diseases, Medication Compliance","enrollment":60},{"nctId":"NCT04564456","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-09-22","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04462822","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-08-24","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT01117116","phase":"NA","title":"Sub-Sensitivity to Long-Acting Bronchodilators (LABA)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2010-03","conditions":"Asthma","enrollment":21},{"nctId":"NCT02826343","phase":"EARLY_PHASE1","title":"New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2016-05-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT03394989","phase":"PHASE3","title":"BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2018-10-17","conditions":"Bronchial Asthma","enrollment":1366},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT03975166","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-05-21","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT00731770","phase":"PHASE4","title":"Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-01","conditions":"COPD","enrollment":10},{"nctId":"NCT03820180","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-01-23","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT01696214","phase":"PHASE4","title":"A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2012-10","conditions":"Asthma","enrollment":20},{"nctId":"NCT03751202","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-11-20","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT03562923","phase":"PHASE3","title":"A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-10","conditions":"Asthma","enrollment":1204},{"nctId":"NCT01290874","phase":"PHASE3","title":"Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03-30","conditions":"Asthma","enrollment":1070},{"nctId":"NCT00273026","phase":"PHASE4","title":"Study In Asthma Control","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2004-11-08","conditions":"Asthma","enrollment":680},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT00214019","phase":"NA","title":"The Effect of Salmeterol on Eosinophil (EOS) Function","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT00461812","phase":"PHASE4","title":"A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2007-04","conditions":"Asthma","enrollment":33},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5677},{"nctId":"NCT02260492","phase":"PHASE1","title":"Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Oriel Therapeutics","startDate":"2014-09","conditions":"Asthma","enrollment":879},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01347060","phase":"","title":"Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Asthma","enrollment":17448},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT00927758","phase":"PHASE2","title":"Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","status":"COMPLETED","sponsor":"Sandoz","startDate":"2009-06","conditions":"Asthma","enrollment":105},{"nctId":"NCT00102882","phase":"PHASE4","title":"Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Asthma","enrollment":547},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00115492","phase":"PHASE4","title":"Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":797},{"nctId":"NCT00328718","phase":"PHASE3","title":"Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Asthma","enrollment":526},{"nctId":"NCT00268216","phase":"PHASE3","title":"Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6228},{"nctId":"NCT01192178","phase":"PHASE4","title":"Fall Epidemic Viral Pediatric Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Asthma","enrollment":339},{"nctId":"NCT00974246","phase":"PHASE4","title":"The Effect on Depressive Symptoms in ECF Residents With COPD","status":"COMPLETED","sponsor":"Valley Medical Research","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease, Depression","enrollment":30},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT00144911","phase":"PHASE4","title":"ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":740},{"nctId":"NCT00296530","phase":"PHASE4","title":"Study Of Patients With Allergic Rhinitis And Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":600},{"nctId":"NCT00400608","phase":"PHASE4","title":"A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT00346749","phase":"PHASE4","title":"ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":180},{"nctId":"NCT00369993","phase":"PHASE2","title":"Spacer Comparison In Adult Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Asthma","enrollment":20},{"nctId":"NCT00920959","phase":"PHASE3","title":"Advair Pediatric Once-Daily","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Asthma","enrollment":908},{"nctId":"NCT01231230","phase":"NA","title":"Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway","status":"COMPLETED","sponsor":"University of Miami","startDate":"2007-05","conditions":"Asthma","enrollment":14},{"nctId":"NCT00385463","phase":"NA","title":"Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2006-04","conditions":"Asthma, Seasonal Allergic Rhinitis","enrollment":""},{"nctId":"NCT01908140","phase":"PHASE3","title":"Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT01921127","phase":"","title":"Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD","enrollment":3000},{"nctId":"NCT00741767","phase":"NA","title":"The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Chronic Obstructive Pulmonary Disease, Sleep Disorders","enrollment":""},{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT00568347","phase":"","title":"Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange","status":"COMPLETED","sponsor":"Arthur F Gelb MD","startDate":"2006-01","conditions":"COPD","enrollment":39},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01907334","phase":"PHASE4","title":"Dose-Response of Salmeterol in Children","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-08","conditions":"Asthma","enrollment":10},{"nctId":"NCT01209715","phase":"PHASE2","title":"Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-10","conditions":"COPD","enrollment":""},{"nctId":"NCT02136875","phase":"PHASE4","title":"Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2008-07","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20170228","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20080731","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20120809","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20141210","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20110627","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20140617","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20130619","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20110104","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20060608","type":"ORIG","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20121219","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20090915","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20171220","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20120809","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20080320","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20141113","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20110510","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20140617","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20100625","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20210818","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"},{"date":"20190107","type":"SUPPL","sponsor":"GLAXO GRP LTD","applicationNumber":"NDA021254"}],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["salmeterol and fluticasone in hydrofluoroalkane (HFA) propellant"],"phase":"marketed","status":"active","brandName":"Advair HFA","genericName":"Advair HFA","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Advair HFA combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchodilation in asthma and COPD. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}